These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer.
    Author: Kunitoh H, Suzuki K.
    Journal: Br J Cancer; 2007 May 21; 96(10):1498-503. PubMed ID: 17473830.
    Abstract:
    The trimodality approach represented by concurrent chemoradiotherapy followed by surgical resection is a highly effective, but potentially toxic therapy for locally advanced non-small-cell lung cancer (NSCLC). In this review, we discuss the current status of this therapy in patients with mediastinal node-positive (N2) stage III NSCLC or superior sulcus tumor, and present an overview of the principles for optimisation of the risk/benefit. Numerous clinical questions remain, and enrolment of patients into well-designed clinical trials should be encouraged.
    [Abstract] [Full Text] [Related] [New Search]